Dr. Brian G. Vikstrom
Claim this profileNorthbay Cancer Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
8 reported clinical trials
19 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage II
Stage III
PD-L1 positive
2Lung Cancer
Stage II
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Brian G. Vikstrom is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
More about Brian G. Vikstrom
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Brian G. Vikstrom has experience with
- Bevacizumab
- Carboplatin
- Irinotecan
- Leucovorin Calcium
- Fluorouracil
- Irinotecan Hydrochloride
Breakdown of trials Brian G. Vikstrom has run
Non-Small Cell Lung Cancer
Lung Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brian G. Vikstrom specialize in?
Brian G. Vikstrom focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage II patients, or patients who are Stage III.
Is Brian G. Vikstrom currently recruiting for clinical trials?
Yes, Brian G. Vikstrom is currently recruiting for 3 clinical trials in Vacaville California. If you're interested in participating, you should apply.
Are there any treatments that Brian G. Vikstrom has studied deeply?
Yes, Brian G. Vikstrom has studied treatments such as Bevacizumab, Carboplatin, Irinotecan.
What is the best way to schedule an appointment with Brian G. Vikstrom?
Apply for one of the trials that Brian G. Vikstrom is conducting.
What is the office address of Brian G. Vikstrom?
The office of Brian G. Vikstrom is located at: Northbay Cancer Center, Vacaville, California 95687 United States. This is the address for their practice at the Northbay Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.